A multi-target
mRNA Vaccine Provides Cross-Prophylactic and Therapeutic Protection
Against Diverse Pasteurellaceae Infections
Xianguo Yi1, 2, Shang Liu3, Yuan Chen4,
Jing Li3, Mengwei Xu3, Qing He3,
Rui Liu3, Tiantian Li3, Lianshun Wang3,
Bo Li6, Xi Li6, Juan Wang7, Shi Xu3
*, Tiyun Han3, 8, 9 * and Zhengli Chen1, 5 *
1College
of Veterinary Medicine, Sichuan Agricultural University, Chengdu,
Sichuan, China; 2College of Animal Science and
Technology, Xinyang Agriculture and Forestry University, Xinyang,
Henan, China; 3Nanjing Chengshi (TheraRNA) Biomedical
Technology Co. Ltd., Nanjing, Jiangsu, China; 4Medical
Oncology, Pingxiang People’s Hospital, Pingxiang, Jiangxi, China;
5Laboratory of Experimental Animal Disease Model, College
of Veterinary Medicine, Sichuan Agricultural University, Chengdu,
Sichuan, China; 6Rong County Animal Husbandry Service
Center, Rongxian Agriculture and Rural Bureau, Zigong, Sichuan,
China; 7School of Foreign Languages, Xinyang Agriculture
and Forestry University, Xinyang, Henan, China; 8School
of Life Sciences, Yunnan Normal University, Kunming, Yunnan, China;
9Engineering Research Center for Valorization of Unique
Bio-Resources in Yunnan, Ministry of Education, Kunming, Yunnan,
China.
Pasteurellaceae
pathogens, including P. multocida, pose significant threats to humans,
livestock, and poultry, while the effectiveness of antibiotic treatment is
gradually being compromised by the problem of antibiotic resistance. Here, we
developed a conserved multi-target mRNA vaccine strategy to achieve
broad-spectrum prevention and therapy against Pasteurellaceae infections.
Six highly conserved intracellular antigens, with truncated sequence
similarities all exceeding 91%, were selected for the development of a novel
mRNA platform against Pasteurellaceae. In mouse models, the vaccine
conferred strong protection against P. multocida and showed
cross-protection against four Pasteurellaceae pathogens, reducing lung
bacterial burden by up to 10-fold compared with the challenge control. In a
rabbit acute pneumonia model, the vaccine significantly improved survival by
over 40% and reduced lung pathology following P. multocida infection.
Notably, repeated administration of vaccine exhibited preliminary therapeutic
efficacy in naturally infected animals, including one cat, piglets (with a 40%
reduction in infection rate), and laying hens (with an approximately 20%
increase in egg production), resulting in bacterial burden and alleviation of
clinical symptoms. These findings demonstrate that a conserved multi-antigen
mRNA vaccine can induce broad-spectrum protective effect against
Pasteurellaceae pathogens.
To Cite This Article:
Yi X, Liu S, Chen Y, Li J, Xu M, He Q, Liu R, Li T, Wang L, Li B, Li X, Wang J,
Xu S, Han
T
and Chen Z, 2026. A multi-target mRNA vaccine provides cross-prophylactic and
therapeutic protection against
diverse Pasteurellaceae infections. Pak Vet J, 46(7): 1678-1694. http://dx.doi.org/10.29261/pakvetj/2026.162